ERS Genomics signed a nonexclusive license agreement with Santa Cruz Biotechnology (SCBT) granting SCBT access to the ERS CRISPR/Cas9 patent portfolio. ERS founder, Emmanuelle Charpentier, PhD, along with Jennifer A. Doudna, PhD, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9.
SCBT, headquartered in Dallas, focuses on research tools and reagents, including monoclonal antibodies, biochemicals, labware, and now CRISPR products.
“CRISPR/Cas9 technology is an exciting advancement for the scientific community. This technology has greatly expanded the possibilities of research. SCBT offers Knock-Out, Activator, and Nickase CRISPR products to most human and mouse protein-encoding genes. The CRISPR product line complements our monoclonal antibody product line,” said John R. Stephenson, president and CEO, SCBT.
“Santa Cruz has an established and impressive reputation for making innovative solutions accessible to scientists. This fully aligns with our core mission of advancing scientific progress and unlocking the full potential of CRISPR/Cas9 in our industry,” added Eric Rhodes, CEO, ERS Genomics, which is based in Dublin.